-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that the first-line treatment of becotolatumab (JMT101) and ositinib developed by the group for locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the epidermal growth factor receptor (EGFR ex20ins) exon insertion mutation (EGFR ex20ins) reached the main end point in the predetermined mid-term analysis and obtained positive top line results. Compared with platinum plus pemetrexed chemotherapy, this product in combination with osidinib significantly lengthened patients' progression-free survival (PFS) and showed a trend of overall survival (OS) benefits.

Zhitongcaijing·09/24/2026 12:33:23
Listen to the news
According to Zhitong Finance App News, Shiyao Group (01093.HK) announced that the first-line treatment of becotolatumab (JMT101) and ositinib developed by the group for locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the epidermal growth factor receptor (EGFR ex20ins) exon insertion mutation (EGFR ex20ins) reached the main end point in the predetermined mid-term analysis and obtained positive top line results. Compared with platinum plus pemetrexed chemotherapy, this product in combination with osidinib significantly lengthened patients' progression-free survival (PFS) and showed a trend of overall survival (OS) benefits.